Nasonex (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the nasal mucosa, suppressing the release of inflammatory mediators such as cytokines and chemokines. This action decreases swelling, mucus production, and the overall inflammatory response within the nasal passages.

The specific dosing regimen for Nasonex is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and response to therapy. Patients should follow the prescriber’s instructions and the product label.

Safety data for mometasone furoate in pregnancy and lactation are limited. The medication should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasonex (mometasone furoate) is a high‑potency intranasal corticosteroid with a favorable safety profile when used at recommended doses. Compared with older agents such as beclomethasone, it offers once‑daily dosing and strong anti‑inflammatory activity, while maintaining low systemic absorption.

Store Nasonex at room temperature, below 25 °C, in its original packaging. Protect the spray from moisture and direct heat. Keep the device upright when not in use and replace the cap securely after each administration.

Nasonex is administered as a nasal spray. The recommended technique is to gently blow the nose, tilt the head slightly forward, insert the tip into one nostril, and press the actuator while breathing in gently through the nose. Repeat in the other nostril if directed by the prescriber.

Serious risks, though rare, include nasal septal perforation, severe allergic reactions such as anaphylaxis, and systemic effects like adrenal suppression when used at high doses for prolonged periods. Patients should report any unusual symptoms promptly to their healthcare provider.

Nasonex should be avoided in individuals with a known hypersensitivity to mometasone furoate or any excipients in the formulation. It is also contraindicated in patients with active untreated nasal infections until the infection has been resolved.